In addition, RAS variants coexisting with BRAF V600E and/or TERT promoter variants tend to be enriched in high-risk cancers, such as thcPTC, FTC, OCA, ATC, and MTC.42,43,44 Third, search for novel molecular markers is needed to screen the rest 29.5% of malignant tumors and 64.4% of thyroid nodules that did not have BRAF V600E, TERT promoter variants, or RAS variants. This evidence concerns the gene BRAF and thyroid cancer, nonmedullary, 2.